Several factors make RUO GLP-1 sales especially risky: The compounds are identical to approved drugs Demand is driven by widespread consumer and clinical use, not niche research Sales volumes often exceed what would be expected for legitimate laboratory research Buyers frequently include wellness clinics, telehealth providers, and resellers rather than research institutions When these facts are present, RUO disclaimers carry little weight
"The use of GLP-1 drugs without medical supervision, including those obtained without a valid prescription, carries potential health risks and may not be suitable for every patient, even among those with type 2 diabetes or obesity
Laboratory research record on GLP-1S [PMID: 39168573] PubMed laboratory record discussing GLP-1S in a research context
The Data: Phase 2 showed ~24% weight loss at 48 weeksthe highest efficacy ever recorded
The first 4 to 8 weeks are usually a dose-escalation phase at lower, "starter" doses designed to allow the body to adjust to side effects like nausea
Insured pricing starts as low as US$25 per month, while cash-paying patients pay from US$149 per month for oral drugs and US$299 per month for injectable treatments such as Wegovy shots and Eli Lillys Zepbound when they pay without insurance